SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Pharmaceuticals reports consolidated net profit of Rs 171.48 crore in Q4

13 May 2016 Evaluate

Glenmark Pharmaceuticals has reported results for the fourth quarter and year ended March 31, 2016.

The company has posted a fall of 24.27% in its net profit at Rs 507.75 crore for the quarter ended March 31, 2016 as compared to Rs 670.43 crore for the same quarter in the previous year. Total income of the company has decreased by 37.53% at Rs 1972.67 crore for quarter under review as compared to Rs 3157.79 crore for the quarter ended March 31, 2015.

On consolidated basis, the company has posted a net profit after taxes, minority interest and share of profit of associates of Rs 171.48 crore for the quarter ended March 31, 2016. Total income of the company stood at Rs 2292.94 crore for the quarter ended March 31, 2016.

For the year ended March 31, 2016, the company has posted a rise of 45.75% in its net profit at Rs 1468.43 crore as compared to Rs 1007.52 crore for the same period in the previous year. Total income of company increased by 20.51% at Rs 6230.78 crore for year under review as compared to Rs 5170.54 crore for the period ended March 31, 2015.  

For the year ended March 31, 2016, on the consolidated basis, the company has posted a net profit after taxes, minority interest and share of profit of associates of Rs 720.10 crore. Total income of the company stood at Rs 7579.99 crore for the year ended March 31, 2016. 

Glenmark Pharma Share Price

2242.80 -5.10 (-0.23%)
20-Apr-2026 11:07 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1674.00
Dr. Reddys Lab 1236.85
Cipla 1237.20
Zydus Lifesciences 941.70
Lupin 2324.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×